4 weeks ago
Development progress of Akida Neural Processor technology, industry partnerships and leadership expansion among highlights of the past year
SAN FRANCISCO–(BUSINESS WIRE)–BrainChip Holdings Ltd. (ASX: BRN), a leading provider of ultra-low power, high-performance AI technology, ended the 2020 calendar year having made significant strides in the development of its technology backed by the launch of its Early Access Program (EAP), availability of Akida™ evaluation boards, new partnerships, and expansion of its executive leadership and global facilities.
The Company’s EAP was launched in June targeting specific customers in a diverse set of end markets in order to ensure availability of initial devices and evaluation systems for key applications. Multiple customers have committed to the advanced purchase of evaluation systems for a range of strategic Edge applications including Advanced Driver Assistance Systems (ADAS) and Autonomous
BrainChip powering artificial nose
BrainChip ‘s AI processor is powering NaNose (Nano Artificial Nose) which tests exhaled breath samples for COVID-19.
Using the NaNose Medical sensor array to collect the data, and Akida to perform the diagnosis, can have a higher rate of reliability than current testing methods and poses less risk to medical professionals because no saliva or mucus samples are collected.
COVID-19 is known to be spread through respiratory droplets, and more recently has been confirmed to be airborne.
Because Akida’s “Edge AI” is a complete neural processor that does not require an external CPU, memory, or Deep Learning Accelerator (DLA), and because it is ultra-low power, it offers a realistic opportunity for an inexpensive hand-held diagnostic testing tool akin to a breathalyzer.